Part II – Colorectal Cancer

Select Publications


Afibercept versus placebo in combination with irinotecan and 5-FU in the treatment of patients with metastatic colorectal cancer after failure of an oxaliplatin based regimen (VELOUR). NCT00561470

Allegra CJ et al. Effects of prior bevacizumab (B) use on outcomes from the VELOUR study: A phase III study of afibercept (Afi) and FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin regimen. Proc ASCO 2012;Abstract 3505.

Arnold D et al. Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: Results of a randomized phase III intergroup study (TML study). Proc ASCO 2012;Abstract CRA3503.


Grothey A et al. Results of a phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer (mCRC) who have progressed after standard therapies. Gastrointestinal Cancers Symposium 2012;Abstract LBA385.

O’Connell M et al. Validation of the 12-gene colon cancer recurrence score (RS) in NSABP C07 as a predictor of recurrence in stage II and III colon cancer patients treated with 5FU/LV (FU) and 5FU/LV+oxaliplatin (FU+Ox). Proc ASCO 2012;Abstract 3512.

Pericay C et al. Phase 2 randomized, noncomparative, open-label, study of afibercept and modified FOLFOX6 in the first-line treatment of metastatic colorectal cancer (AFFIRM). ESMO 14th World Congress on Gastrointestinal Cancer 2012;Abstract O-0024.

Ross JS et al. Use of next-generation sequencing (NGS) to detect a novel ALK fusion and a high frequency of other actionable alterations in colorectal cancer (CRC). Proc ASCO 2012;Abstract 3533.

Salazar R et al. The PARSC trial, a prospective study for the assessment of recurrence risk in stage II colon cancer (CC) patients using ColoPrint. Gastrointestinal Cancers Symposium 2012;Abstract 678.


Van Cutsem E et al. Intravenous (IV) afibercept versus placebo in combination with irinotecan/5-FU (FOLFIRI) for second-line treatment of metastatic colorectal cancer (MCRC): Results of a multinational phase 3 trial (EFC10262-VELOUR). ESMO 13th World Congress on Gastrointestinal Cancer 2011;Abstract 0-0024.